Zymeworks (ZYME) Total Current Liabilities (2021 - 2026)
Zymeworks (ZYME) reported Total Current Liabilities of $35.6 million for Q1 2026, down 45.24% on a YoY basis from $65.1 million in Q1 2025, and down 15.76% sequentially from $42.3 million in Q4 2025.
Zymeworks (ZYME) Total Current Liabilities (2021 - 2026) Analysis & Trends
Zymeworks (ZYME) has 6 years of Total Current Liabilities data on file, last reported at $35.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities fell 45.24% year-over-year to $35.6 million; the trailing twelve-month figure through Mar 2026 stood at $35.6 million (down 45.24% YoY), and the FY2025 full-year result was $42.3 million, down 52.07% from the prior year.
- Total Current Liabilities slipped to $35.6 million in Q1 2026, from $42.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $95.6 million in Q4 2022 to a low of $35.6 million in Q1 2026.
- A 5-year average of $63.3 million and a median of $57.7 million in 2022 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 58.34% in 2024 and sank 52.07% in 2025, its largest moves.
- Tracing ZYME's Total Current Liabilities over 5 years: stood at $95.6 million in 2022, then tumbled by 41.69% to $55.8 million in 2023, then jumped by 58.34% to $88.3 million in 2024, then tumbled by 52.07% to $42.3 million in 2025, then slipped by 15.76% to $35.6 million in 2026.
- Business Quant data shows ZYME's Total Current Liabilities at $35.6 million in Q1 2026, $42.3 million in Q4 2025, and $42.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 66.94 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 13.42 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.81 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 289.60 Mn |
| 10 | Zymeworks | 1.70 Bn | 1.34 Bn | - | 35.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.65 Mn |
| Dec 31, 2025 | 42.32 Mn |
| Sep 30, 2025 | 42.04 Mn |
| Jun 30, 2025 | 38.50 Mn |
| Mar 31, 2025 | 65.10 Mn |
| Dec 31, 2024 | 88.29 Mn |
| Sep 30, 2024 | 83.91 Mn |
| Jun 30, 2024 | 54.71 Mn |
| Mar 31, 2024 | 56.89 Mn |
| Dec 31, 2023 | 55.76 Mn |
| Sep 30, 2023 | 72.85 Mn |
| Jun 30, 2023 | 93.55 Mn |
| Mar 31, 2023 | 67.32 Mn |
| Dec 31, 2022 | 95.63 Mn |
| Sep 30, 2022 | 57.71 Mn |
| Dec 31, 2021 | 71.85 Mn |